CDK12: a potential therapeutic target in cancer

Simple item page
dc.contributor.authorEmadi, F.
dc.contributor.authorTeo, T.
dc.contributor.authorRahaman, M.H.
dc.contributor.authorWang, S.
dc.date.issued2020
dc.description.abstractCyclin-dependent kinase (CDK) 12 engages in diversified biological functions, from transcription, post-transcriptional modification, cell cycle, and translation to cellular proliferation. Moreover, it regulates the expression of cancer-related genes involved in DNA damage response (DDR) and replication, which are responsible for maintaining genomic stability. CDK12 emerges as an oncogene or tumor suppressor in different cellular contexts, where its dysregulation results in tumorigenesis. Current CDK12 inhibitors are nonselective, which impedes the process of pharmacological target validation and drug development. Herein, we discuss the latest understanding of the biological roles of CDK12 in cancers and provide molecular analyses of CDK12 inhibitors to guide the rational design of selective inhibitors.
dc.description.statementofresponsibilityFatemeh Emadi, Theodosia Teo, Muhammed H. Rahaman and Shudong Wang
dc.identifier.citationDrug Discovery Today, 2020; 25(12):2257-2267
dc.identifier.doi10.1016/j.drudis.2020.09.035
dc.identifier.issn1359-6446
dc.identifier.urihttps://hdl.handle.net/2440/135204
dc.language.isoen
dc.publisherElsevier
dc.rights© 2020 Elsevier Ltd. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.drudis.2020.09.035
dc.titleCDK12: a potential therapeutic target in cancer
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Pharmacology publications